Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-051 in advanced head and neck cancer
NCT02079324Phase 1Completed
- Sponsor
- Genexine
- Start
- Mar 2014
- Primary completion
- Sep 2016
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of il-12-transfected mesenchymal stem cells in head and neck cancer (HNC), sponsored by Genexine. Primary endpoint: Maximum Tolerable Dose at 2 months. Started Mar 2014; status: completed.
02
Drugs
il-12-transfected mesenchymal stem cells
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02079324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079324.